Nuvilex (NASDAQ:PMCB) Trading 1.1% Higher – Still a Buy?

Nuvilex Inc. (NASDAQ:PMCB) shares rose 1.1% on Tuesday . The stock traded as high as $0.80 and last traded at $0.7763. 78,219 shares traded hands during mid-day trading, a decline of 43% from the average session volume of 137,018 shares. The stock had previously closed at $0.7681.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Nuvilex in a research note on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has an average rating of “Sell”.

Nuvilex Stock Up 1.1%

The firm has a 50 day moving average of $0.76 and a 200-day moving average of $0.78. The company has a market cap of $8.34 million, a P/E ratio of -0.69 and a beta of 0.51.

Nuvilex Company Profile

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.